Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 6
Submit an article Journal homepage
115
Views
67
CrossRef citations to date
0
Altmetric
Research Article

P-glycoprotein in Acute Myeloid Leukaemia: Therapeutic Implications of its Association With Both a Multidrug-resistant and an Apoptosis-resistant Phenotype

Monica Pallis Academic Haematology, Clinical Sciences Building, Nottingham City Hospital, Nottingham NG5 IPB, UK
,
Julie Turzanski Academic Haematology, Clinical Sciences Building, Nottingham City Hospital, Nottingham NG5 IPB, UK
,
Yutaro Higashi Academic Haematology, Clinical Sciences Building, Nottingham City Hospital, Nottingham NG5 IPB, UK
&
Nigel Russell Academic Haematology, Clinical Sciences Building, Nottingham City Hospital, Nottingham NG5 IPB, UK
Pages 1221-1228 | Published online: 01 Jul 2009

  • Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. and Piere, D. (1992) "Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukaemia cells at diagnosis". Blood 79, 473, 476.
  • Nussler, V., Pelka-Fleischer, R., Zwierzina, H., Nerl, C., Beckert, B., Gieseler, F., Diem, H., Ledderose, O., Gullis, E., Sauer, H. and Wilmanns, W. (1996) "P-glycoprotein expression in patients with acute leukemia-clinical relevance". Leukemia 10, S23-S31.
  • Del Poeta, G., Stasi, R., Aronica, G., Vendttti, A. Cox, M.C., Bruno, A., Buccisano, F., Masi, M., Tribalto, M., Amadori, S. and Papa, G. (1996) "Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia". Blood 87, 1997-2004.
  • Hunault, M., Zhou, D., Delmer, A., Ramond, S., Viguie, F., Cadiou, M., Perrot, J.Y., Levy, V., Rio, B., Cymbalista, F. Ziuoun, R. and Marie, J.P. (1997) "Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment". Ann. Hematol. 74, 65-71.
  • Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T. Slovak. M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. and Willman, C.L. (1997) "Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDRI) and cytogenecics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy A southwest oncology group study". Blood 89, 3323-3329.
  • Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, I., Slovak, M.L., McConnell, T.S., Head, D.R., Weick, J., Grever, M.R., Appelbaum, FR. and Willman, C.L. (1999) "Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRPI, and LRP in acute myeloid leukemia: a southwest oncology group study". Blood 94, 1086-1099.
  • van den Heuvel-Eibrink, M.M., van der Holt, B., te Boekhorst, P. A.W., Pieters, R., Schoester, M., Lowenberg, B. and Sonneveld, P. (1997) "MDR 1 expression is an independent prognostic factor for response and survival in de novo acute mycloid leukaemia". Br. J. Haematol 99, 76-83.
  • Del Poeta, G., Venditti, A., Stasi, R., Aronica, G., Cox, M.C., Buccisano, F. Tamburini, A., Bruno, A., Maunllo, L., Battaglia, A. Suppo, G., Epiceno, A.M., Del Moro, B., Masi, M., Amadori, S. and Papa, G. (1999) "P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogeneric risk classes in acute myeloid leukemia". Leuk. Res. 23, 451-465.
  • Wuchter, C., Karawajew, L., Ruppert, V. Buchner, T., Schoch, C., Haferlach, T., Ratei, R. Dorken, B. and Ludwig, W.D. (1999) "Clinical significance of CD95. Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoproiein function, maturation stage, and cytogenetics". leukemia 13, 1943-1953.
  • Filipits, M., Stranzl, T., Pohi, G., Heinzl, H. Jager, U., Geissler, K., Fonatsch, C., Haas, O.A., Lechner, K. and Pirker, R. (2000) "Drug resistance factors in acute myeloid leukemia: a comparative analysis". Leukemia 14, 68-76
  • Sievers, E.L., Smith, FO., Woods, W.G., Lee, J.W., Bleyer, W.A., Willman, C.L. and Bernstein, I.D. (1995) "Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia tails to define a poor prognostic group: a report from the Childrens Cancer Group", Leukemia 9, 2042-2048.
  • List, A.F., Kopecky, KJ., Willman, C.L., Head, D.R., Persons, Dl.,. Slovak, M.L., Dorr, R., Karanes, C., Hynes, H.E., Doroshow, J.H., Shurafa, M. and Appelbaum, F.R., (2001) "Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncolcogy Group study". Blood 98, 3212-3220.
  • Liu Yin, J.A., Wheatley, K., Rees, J.K. and Burnett, A.K. (2001) "Comparison of 'sequential' versus 'standard' chemotherapy as reinduction treatment, with or without cyclosporine. in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial". Br: J. Haematol. 113, 713-726.
  • Baer, M.R., George, S.L., Dodge, R.K., Cooke, K., Caligiuri, M.A., Powell, B.I.,. Kolitz, J.E., Schiffer. C.A. and Larson, R.A. (1999) "Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute mycloid leukemia (AMI.) patients (pts) 60 years (CALGB 9720)". Blood 94, 383a.
  • Smeets, M., Haymakers, R., Muus, P., Vierwinden, G., Linssensen, P., Masereeuw, R. and de Witte, T. (2001) "Cyclosporin increases cellular idurubiein and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance". Leukemia 15, 80-88.
  • Verdonek, L.F., Lokhorst, H.M., Roovers, D.J. and vanHeugten, H.G. (1998) "Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunontbiein implications for liposotne-encapsulated daunorubicin". Leuk. Res. 22, 249-256.
  • Michieli, M., Darniani, D., Ermacora, A., Masolini, P., Michelutli, A., Michelutli, T., Russo, D., Pea, F. and Baccarani, M. (1999) "Liposome-encapsulated daunorubicin for PGP-related multidrug resistance". Br. J. Haematol. 106, 92-99.
  • Vignetri, M., Tafuri, A., Fazi, P., Amadori, S., Camera, A., Ferrara, F., Fioritoni, G., Mariani, G., Pagano, L., Piccaluga, P., Romano, A., Russo, D., Spccchia, G., Zaccaria, A., Baccarani, M. and Mandelli, F. (2000) "Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia. The GIMEMA experience". Exp. Hematol. 28, 1501-1502.
  • Bellott, R., Auvrignon, A., Leblane, T., Perel, Y., Gandeiner, V., Bertrand, Y., Mechinaud, R. Bellenger, P., Vernois, J., Leverger, G., Baruchel, A. and Robert, J. (2001) "Pharmacokinelics of liposomal daunorubicin (DaunoXome) during a phase 1-11 study in children with relapsed acute lymphoblastic leukaemia". Cancer Chemother. Pharmacol. 47, 15-21.
  • Willman, C.L. (2001) "Targeted AML therapy: new biologic paradigms and therapeutic opportunities". Leukemia 15, 690-694.
  • Larson, R.A. (2001) "New agents for induction and postremission therapy of acute myeloid leukemia", Leukemia 15, 675-676.
  • Visarti, G., Tosi, P., Zinzani, P.L., Manfroi, S., Ottaviani, E., Testoni, N., Clavio, M., Cenacchi, A. Gnmberi, B., Carrara, P., et al., (1994) "FLAG (fludarabine 4 high-dose cylarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid lcukcmias", Leukemia 8, 1842- 1846.
  • Gandhi, V., Esicy, E., Du, M., Nowak, B., Keating, M.J. and Plunkett, W. (1995) "Modulation of the cellular metabolism of cytarabine and fludarabuie by granulocyie-colony-stiinulating factor during therapy of acute myelogenous leukemia", Clin. Cancer Res. 1, 169-178.
  • Parker, J.E., Pagliuca, A., Mijovic, A., Cullis, J.O., Czepulkowski, B., Rassam, S.M., Samaratunga, I.R., Grace, R., Gover, P.A. and Mufti, G.J. (1997) "Fludarabine. cylarabine. G-CF and idaruhicin (FLAG-IDA) for the treatment of poor-risk myelodyspfastic syndromes and acute myeloid leukemia". Br. J. Haematol. 99. 939-944.
  • Jackson, G., Taylor, P., Smith, G.M., Marcus, R., Smith, A., Chu, P., Littlewood, T.J., Duncombek A., Hutchinson, M., Mehta, A.B., Johnson, S.A., Carey, P., Mackic, M.J., Ganly, P.S., Turner, G.E., Diane, M., Schey, S., Brookes, J., Tollerfield, S.M. and Wilson, M.P. (2001) "A multicentre. open, non-comparative phase Il study of a combination of fludarabine phosphate, cylarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation", Br: J. Haemato. 112, 127-137.
  • Gandhi, V. Estey, E., Keating, M. und Plunkett, W. (1993) "Fludarabine potentiates metabolism of cytarabine in patients with acute myclogenouus leukaemia during therapy". J. Clin. Ontol. 11, 116-124.
  • Visani, G., Tosi, P., Zinzani, P.L. Manfroi, S., Otlaviani, E., Cenacchi, A., Carrara, P., Clavio, M., Gobbi, M. and Tura, S. (1996) "FLAG (fludarabine. cylarabine. G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: In vitro and in vivo effects". Eur. J. Haematol. 56, 308-312.
  • Michelutti, A., Michieli, M., Damiani, D., MeIIi, C. Ermacoro, A., Grimaz, S., Candoni, A., Russo, D., Fanin, R. and Baccarani, M. (1997) "Effect of fludarabine and arabinosylcytosine on multidrug resistant cells". Haematologica 82, 143-147.
  • Higashi, Y., Turzanski, J., Pallis, M. and Russell, N.H. (2000) "Contrasting in vitro effects for the combination of fludarabine. cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia". Br. J. Haematol 111, 565-569.
  • Berman,E. and McBride, M. (1992) "Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistam leukemia cells". Blood 79, 3267-3273.
  • Michieli, M., Michelutt, A., Daniani, D., Pipan, C., Raspadori, D., Lauria, F. and Baccarani, M. (1993) "A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives". Lenk. Lymphoma 9, 255-264.
  • Pogliani, E.M., Carpenedo, M., Miccolis, I., Belotti, D. and Comeo, G.M. (2001) "P-glycoprotein expression in acute myeloid leukaemia cells al diagnosis: its relationship to daunorubiciu or idarubiein induction therapy and survival; malignancy", Hermatology 5, 359-367.
  • Fleischhack, C., Hasan, C., Graf, N., Munn, G. and Bode, U. (1998) "IDA-FLAG (idarubicin. fludarabine. cytarabine. G-CSF). an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow lransplanlation: experiences of a phase 11 trial". Br. J. Haematol. 102, 647-655.
  • Steinmetz, H.T., Schulz, A., Staib, P., Scheid, C., Glasmacher, A., Neufang, A., Franklin, J., Tesch, H., Dichl, V. and Dias Wickramanayake, P. (1999) "Phase-II trial of idarubicin. fludarabine. cytosine arabinoside. and rilgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML". Ann. Hematol. 78, 418-425.
  • Russo, D., Pricolo, G., Michieli, M., Michelutti, A., Raspadori, D. Bertone, A., Marin, L., Pierri, I., Bucalossi, A., Zulfa, E., De Vivo. A, Mazza, P., Gobbi, M., Launa, F., Zaccaria, A. and Baiccarani, M. (2001) "Fludarabine, arabmosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute inyeloid leukemia". Lenk. Lymphuma 40, 335-343.
  • Lenz, M., Miene, W.P., Vahrenwald, F., Bruchelt, G., Schweizer, P. and Girgert, R. (1997) "Cholesterol based antineoplastic strategies". Anticancwer Res. 17, 1143-1146
  • Holstein, S.A. and Hohl, R.J. (2001) "Interaction of cytosine arabinoside and lovastatin in human leukemia cells". Lenk. Res. 25, 651-660.
  • Xia, Z., Tan, M.M., Wong, W.W., Dimiiroulakos, J., Minden, M.D. and Penn, L.Z. (2001) "Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells". Leukemia 15, 1398-1407.
  • Newman, A., Clutterbuck, R.D., Powles,. R.L., Catovsky, D. and Millar, J.I., (1997) "A comparison of the effect of the 3-hydroxy3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin. lovastatin and pravaslatin on leukaemia and normal bone marrow progenitors". Lenk. Lymphoma 24, 533-537.
  • Dimitroulakos, J., Nohynek, D., Backway, K., Hedley, D., Yeger, H., Freedman, M., Minden, M. and Penn, L. (1999) "Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach". Blood 93, 1308-1318.
  • Maksumova, L., Ohnishi, K., Muratkhodjaev, F. Zhang, W., Pan, L., Takeshita, A. and Ohno, R. (2000) "Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin". Leukemia 14, 1444-1450.
  • Parker, P.J. (1999) "Inhibition of protein kinase C- do we. can we. and should we?''. Pharmacol. Ther. 82, 263-267.
  • Jarvis, W.D. and Grant, S. (1999) "Protein kinase C targeting in antincoplastic treatment strategics". Investig. New Drugs 17, 227-240.
  • Sharkis, S.J., Jones, R.J., Bellis, M.L., Demetri, G.D., Griffin, J.D., Civin, C. and May, W.S. (1990) "The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors". Blood 76, 716-720.
  • Jones, R.J., Sharkis, S.J., Miller, C.B., Rowinsky, E.K., Burke, P.J. and May, W.S. (1990) "Bryosiatin 1. a unique biologic response modifier: anti-leukemic activity invitro". Blood 75, 1319-1323.
  • Matsui, W., Gladstone.D., Vala, M., Barber, J.,Brodsky, R.,Smith, D. and Jones, R. (2000) 'Tumor cell terminal differentiation requires cell cycle inhibition combined with growth factors". Blood 96, 309a.
  • Tainton, K.M., Rucfli, A.A., Smyth, M.J. and Johnstone, R.W. (2000) "Equivalent death of P-glycoprotein expressing and nonexpressing cells induced by the protein kinase C inhibitor staurosporine". Biochem. Biophys. Res. Commun. 276, 231- 237.
  • Fine, R.L., Chambers, T.C. and Sachs, CW (1996) "P-glycoprotem. multidrug resistance and protein kinase C". Oncologist 1, 261-268.
  • Laredo, J., Huynh, A., Muller, C., Jaffrezou, J.P., Bailly, J.D., Cassar, G., Laurent, G. and Demur, C. (1994) "Effect of the protein kinase C inhibitor siaurosporine on chemosensitivity to daunorubicin of normal and letikemic fresh myeloid cells", Blood 84, 229-237
  • Jing, Y. Dai, J., Chalmers-Redman, R.M., Tatton, W.O. and Waxman. S. (1999) "Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxidedependent pathway". Blood 94, 2102-2111.
  • Lu, M., Levin, J., Sulpice, E., Sequeira-Le Grand, A., Alemany, M., Caen, J.P. and Han, Z.C. (1999) "Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines", Exp. Hematol. 27, 845-852.
  • Perkins, C., Kim, C.N., Fang, G.F. and Bhalla, K.,N. (2000) "Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR. MRP, Bcl-2, or BCIX(L)". Blood 95, 1014-1022.
  • Smith, B.D., Bambach, B.J., Vala, M.S., Barber, J.P., Eager, C., Brodsky, R.A., Burke, P.J., Gore, S.D. and Jones, R.J. (1998) "Inhibited apoptosis and drug resistance in acute myeloid leukaemia". Br J. Haematol. 102, 1042-1049.
  • Pallis, M. and Russell, N. (1999) "P-glycoprotein expression is associated with resistance to spontaneous in vitro apoptosis in AML". Leukemia 13, 1468-1469.
  • Pallis, M., Zhu, Y.M. and Russell, N.H. (1997) "Bcl-x[L] is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in mini and with P-glycoprotein expression", Leukemia 11, 945-949.
  • Robinson, L.J., Roberts, W.K., Ling, T.T., Lamming, D., Sternberg, S.S. and Roepe, P.D. (1997) "Human MDR I protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts". Biochemistry 36, 11169-11178.
  • Smyth, M., Krasovskis, E., Sutton, V. and Johstone, R. (1998) 1998) "The drug efflux protein, P-glycoprotein, additionally protects drugresistant tumor cells from multiple forms of caspase-dependent apoptosis". Prac. Natl. Acad. Sci. USA 95, 7024-7029.
  • Johnstone, R., Cretney, E. and Smyth, M. (1999) "P-glycoprotein protects leukemia cells against caspasc-dependent, but not caspaseindependent. cell death". Blood 93, 1075-1085.
  • Pallis, M. and Russell, N. (2000) "P-gJl coprotein plays a drugefaux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway". Blood 95, 2897-2904.
  • Jaffrezou, J.P., Levade, T. Bettaieb, A., Andrieu, N., Bezombes, C., Maestre, N., Vermeersch, S., Rousse, A. and Laurent, G. (1996) "Daunorubicin-induced apoptosis-triggering of ceramide generation through sphingomyelin hydrolysis", Embo J. 15, 2417-2424.
  • Bose, R., Verhij, M., Haimovitz-Fricdman, A., Scotto, K., Fuks, Z. and Kolesnick, R. (1995) "Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating cell death signals". Cell 82, 405-414.
  • van Helvoort, A., Smith, A.J., Sprong, H., Fritzsche, I., Schinkel, A.H., Borst, P. and van Meer, G. (1996) "MDR1 P-glycopratein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine". Cell 87, 507-517.
  • Bosch, I., Dunussi-Joannopoulos, K., Wu, R.L., Furlong, S.T. and Croop, J. (1997) "Phosphatidylcholine and phosphatidylethanolatnine behave as substrates of the human MDRl P-glycoprotein". Biochemistry 36, 5685-5694.
  • Bezomhes, C., Maestre, N., Laurent, G., Levade, T. Bettaieb, L. and Jaffrezou, J.-P. (1998) "Restoration of TNF-a-induccd ceramide generation and apoptosis in resistant leukemia KGIa cells by the p-glycoprotein blocker PSC833", FASEB J. 12, 101-109.
  • Flicker, G. and Fahr, A. (1997) "Mechanisms of hepatic transport of cyclosporin A: an explanation for its cholestalic action?", Yale J. Biol. Med. 70, 379-390.
  • Goulding, C.W., Giuliano, A.E. and Cabot, M.C. (2000) "SDZ PSC S33 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein". Cancer Lett. 149, 143-151.
  • Grey, M., Borg, A.G., Wood, P., Burgess, R., Fisher, A. and Yin, J.A.L. (1997) "Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cylotoxic agents in acute myeloid leukaemia". Leuk. Res. 21, 867-874.
  • Lavi,. Y., Cao, H. Volner, A., Lucci, A., Han, T.Y., Geffen, V., Giuliano, A.E. and Cabo;. M.C. (1997) "Agents that reverse mullidrug resistance, tamoxifen. verapamil. and cyclasporin A. block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells", J Biol. Client. 272, 1682-1687.
  • Nicholson, K.M., Quinn, D.M., Kellen, G.L. and Warr, J.R. (1999) "Preferential killing of multidrug-resislant KB cells by inhibitors of glucosylceramide synthase". Br. J. Cancer 81, 423-30.
  • Lala, R. Ito. S. and Lingwood, C.A. (2000) "Retroviral transfection of Madin-Darby canine kidney cells with human MDRI results in a major increase in globotriaosylceramide and 10(5)- to I0< 6)-fold increased cell sensitivity to verocytotoxin. Role ofp-glycoprotein in glycolipid synthesis", J. Biol. Chem. 275, 6246-6251.
  • Molinari, A., Cianrriglia, M., Meschini, S., Culcabrini, A. and Arancia. G. (1994) "P-glycoprotein expression in the golgi apparatus of mullidrug-resistant cells". Int. J. Cancer 59, 789-795.
  • Cullis, P., Hope, M., Bally, M., Madden, T., Mayer, L. and DB, F. (1997) "Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellor vesicles". Biochem. Biophys. Acta 1331, 187-211.
  • Keizer, H.G. and Joenje, H. (1989) "Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil", J. Natl. Cancer lnst. 81, 706-709.
  • Boscoboinik, D., Gupta, R.S. and Epand, R.M. (1990) "Investigation of the relationship between altered imracellular pH and multidrug resistance in mammalian cells". Br. J. Cancer 61. 568-572.
  • Thiebaul, F., Curriei, S., Whitaker, J., Haugland, R., Gottesman, M., Pastaqn, I. and Willingham, M. (1990) "Activity of the multidrop transporter results in alklinazation of the cytosol: measurement of cytosolic pH by microinjection of a pH-sensitive dye", J. Histochem, Cytochem. 5, 685-690.
  • Altenberg, G.A., Young, G., Horton, J.K., Glass, D., Belli, J.A. and Reuss, L. (1993) "Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance". Proc, Natl. Acad. Sci. USA 90, 9735-9738.
  • Litman, T., Pedersen, S.F., Kramhoft, B., Skovsgaard, T. and Hoffmann, E.K. (1998) "pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells", Cell Physiol. Biochem. 8, 138-150.
  • Hoffman, M.M., Wei, L. Y. and Roepe, P.D. (1996) "Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance?". J. Gen. Physiol. 108, 295-313.
  • Chen, Y. and Simon, S.M. (2000) "In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity". J. Cell Biol. 148, 863-870.
  • Shrode, L.D., Tapper, H. and Grinstein, S (1997) 'Role of intracellular pH in proliferation, transformation, and apoptosis", J. Bioenerg. Biomembr. 29, 393-399.
  • Idriss, H.T., Hannun, Y.A., Boulpaep, E. and Basavappa, S. (2000) "Regulation of volume-activated chloride channels by P-glycoprotein: phosphorylation has the final say!", J. Physiol. 524(Pt 3), 629-636.
  • Drach, J., Gsur, A., Hamilton, G., Zhao, S., Angerler, J., Fiegl, M., Zojer, N., Rederer, M., Haberl, I., Andreeff, M. and Huber, H. (1996) "Involvement of P-glycoprotein in the transmembrane transport of intericukin-2 (IL-2). II.-4. and interferon-gamma in normal human T lymphocytes". Blood 88, 1747-1754.
  • Raghu, G., Park, S.W., Roninson, I.B. and Mechetner, E.B. (1996) "Monoclonal antibodies against P-glycoprotein. an MDR1 gene product. Inhibit interlcukin-2 release from PHA-activated lymphocytes". Exp. Hematol. 24, 1258- 1264.
  • Gollapudi, S., Kim, C. and Gupta, S. (2000) "P-glycoprotein (encoded by multidrug resistance genes) is not required for interleukin-2 secretion in mice and humans". Genes Immun, 1, 371-379.
  • te Boekhorst, P.A.W., Lowenberg, B., Vankapel, J., Nooter, K. and Sonneveld, P. (1995) "Multidrug-resistant cells with high proliferative capacity determine response to therapy in acute mycloid-leukemia". Leukemia 9, 1025-1031.
  • del Canizo, M.C., Brufau, A., Almeida, J., Galende, J., Garcia Marcos, M.A., Mola. A., Garcia, R., Femandez Calvo, J., Ramos, F. Fisac, P., Orfao, A. and San Miguel, J.F. (1998) "In vitro growth in acute myeloblastic leukaemia: relationship with other clinicobiological characteristics of the disease". Br. J. Haematol. 103, 137-142.
  • Bunting, K., Galipcau, J., Topham, D., Benaim, E. and Sorrentino, B. (1998) "Transduction of marine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a mycloproliferative syndrome in transplanted mice". Blood 92, 2269-2279.
  • Paietta, E., Andersen, J., Racevskis, J., Ashigbi, M., Cassilelh, P. and Wiernik, P.H. (1995) "Modulation of multidrug resistance in de novo adult acute myeloid laukacmia: variable efficacy of reverting agents in vitro". Blood Rev. 9, 47-52.
  • Leith, C.P., Chen, I.M., Kopecky, K.J., Appelbaum, F.R., Head, D.R., Godwin, J.E., Weick, J.K. and Willman, C.L (1995) "Correlation of multidrug resistance (MDRI) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR -/efflux + and MDRI+/efflux - cases". Blood 86, 2329-2342.
  • Michieli, M., Damiani, D., Ermacora, A., Raspadori, D., Michelutti, A., Grimaz, S., Fanin, R., Russo, D., Lauria, F., Masolini, P. and Baccarani, M. (1997) "P-glycoprotein (pgp) and lung resistancerelated protein (LRP) expression and function in leukaemic blast cells". Br. J. Haemawi. 96, 356-365.
  • Pulsford, J.F.F., Sargent, J.M., Elgie, A.W., Williamson, C.J. and Taylor, C.G. (1995) "Comparison of p-glycoprotein expression with in vitro drug-sensitivity in fresh blast cells from acute myeloid-leukemia patients". Br. J. Biomedical Sci. 52, 188-194.
  • Broxterman, H., Sonneveld, P., Pielers, R., Lankelma, J. Eekman, C., Loonen, A., Schoester, M., Ossenkooppele, G., Lowenberg, B., Pinedo, H. and Schuurhuis, G. (1999) "Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubiein resistance in acute myeloid leukemia?". Leukemiu 13, 258-265.
  • Norgaard, J., Bukh, A., Langkjer, S.T., CIausen, N., Palshof, T. and Hokland, P. (1998) "MDRl gene expression and drug resistance of AML cells". Br. J Haematol, 100, 534-540.
  • van den Heuvel-Eibrink, M.M., Wiemer, E.A., de Boevere, M.J., van der Holt, B., Vossebeld, P.J., Pieters, R. and Sonneveld, P. (2001) "MDRI gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia". Blood 97, 3605-3611
  • Wang, J.L., Liu, D., Zhang, Z.J., Shan, S., Han, X., Srinivasula, S.M., Croce, C.M., Alnemri, E.S. and Huang, Z. (2000) "Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells". Proc. Natl. Acad. Sci. USA 97, 7124-7129.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.